Showing results (491-500 of 558) with videos related to
Sort By:
Pageof 56
Pediatric Blood & Cancer|February 3, 2021
Safety and efficacy of concurrent carboplatin during full-dose craniospinal irradiation for high-risk/metastatic medulloblastoma in a resource-limited settingTejpal Gupta, Shwetabh Sinha, Girish Chinnaswamy, et al.Harmful Algae|August 20, 2025
Paralytic shellfish toxins and seabirds: evaluating sublethal effects, behavioral responses, and ecological implications of saxitoxin ingestion by common murres (Uria aalge)Matthew M Smith, Robert J Dusek, Tuula Hollmen, et al.Ecancermedicalscience|January 21, 2026
Is active surveillance a good treatment option for stage 1 seminoma in a developing nation? Long-term outcomes from the Indian subcontinentAditya Dhanawat, Debdeep Samaddar, Bhagyashri Jadhav, et al.Indian Journal of Cancer|March 14, 2020
Indian clinical practice consensus guidelines for the management of squamous cell carcinoma of head and neckKumar Prabhash, Govind Babu, Pankaj Chaturvedi, et al.Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancerLuis G Paz-Ares, Maurice Pérol, Tudor-Eliade Ciuleanu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2026
Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder CancerVedang Murthy, Priyamvada Maitre, Mahendra Pal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2021
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled TrialVedang Murthy, Priyamvada Maitre, Sadhana Kannan, et al.Frontiers in Oncology|April 30, 2026
MRI-based tumor signatures as prognostic biomarkers in oral tongue squamous cell carcinomaNivedita Chakrabarty, Nithin Krishnan, Abhishek Mahajan, et al.Lung Cancer (Amsterdam, Netherlands)|April 28, 2026
Asia-Pacific practical consensus in the management of adverse events related to amivantamab-based therapies in non-small cell lung cancerRoss A Soo, Pablo Fernandez-Penas, Molly Li, et al.South Asian Journal of Cancer|December 31, 2025
Real-World Experience of First-Line Osimertinib in EGFR Mutated Non-Small Cell Lung Cancers from a Tertiary Cancer Center, IndiaAtul Tiwari, Ajay Kumar Singh, Vanita Noronha, et al.Pageof 56